MedTrace Logo

N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

NCT00637624 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2022-08-25

No results posted yet for this study

Summary

In this study we want to investigate the efficacy of N-acetylcysteine (NAC), which is an anti-oxidant, in the prevention of cisplatin-induced neural toxicity, in patients treated for lung cancer with chemotherapy containing cisplatin.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Small Cell Lung
  • Mesothelioma

Interventions

DRUG

N-Acetylcysteine

N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg

DRUG

Placebo

Placebo once every 3 weeks intravenous saline fluid

Sponsors & Collaborators

  • Rijnstate Hospital

    lead OTHER

Principal Investigators

  • Idris Bahce, MD · Rijnstate Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00637624 on ClinicalTrials.gov